Eluxadoline
|
- $63 - $640
- Product name: Eluxadoline
- CAS: 864821-90-9
- MF: C32H35N5O5
- MW: 569.65
- EINECS:1592732-453-0
- MDL Number:MFCD28386164
- Synonyms:JNJ 27018966;Eluxadoline;5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid;Eluxadolin;API-Diarrhea;Benzoic acid, 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxy-;CS-2329;Eluxadoline (Viberzi)
7 prices
Selected condition：
Brand
- American Custom Chemicals Corporation
- Cayman Chemical
- DC Chemicals
- TRC
Package
- 5MG
- 10mg
- 25mg
- 50mg
- 100mg
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberAPI0027379
- Product descriptionELUXADOLINE 95.00%
- Packaging5MG
- Price$504.41
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number21522
- Product descriptionEluxadoline ≥98%
- Packaging10mg
- Price$63
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number21522
- Product descriptionEluxadoline ≥98%
- Packaging25mg
- Price$149
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number21522
- Product descriptionEluxadoline ≥98%
- Packaging50mg
- Price$280
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number21522
- Product descriptionEluxadoline ≥98%
- Packaging5mg
- Price$293
- Updated2021-12-16
- Buy
- ManufacturerDC Chemicals
- Product numberDC8626
- Product descriptionEluxadoline >98%
- Packaging100mg
- Price$350
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberE508195
- Product descriptionEluxadoline
- Packaging100mg
- Price$640
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| American Custom Chemicals Corporation | API0027379 | ELUXADOLINE 95.00% | 5MG | $504.41 | 2021-12-16 | Buy |
| Cayman Chemical | 21522 | Eluxadoline ≥98% | 10mg | $63 | 2021-12-16 | Buy |
| Cayman Chemical | 21522 | Eluxadoline ≥98% | 25mg | $149 | 2021-12-16 | Buy |
| Cayman Chemical | 21522 | Eluxadoline ≥98% | 50mg | $280 | 2021-12-16 | Buy |
| Cayman Chemical | 21522 | Eluxadoline ≥98% | 5mg | $293 | 2021-12-16 | Buy |
| DC Chemicals | DC8626 | Eluxadoline >98% | 100mg | $350 | 2021-12-16 | Buy |
| TRC | E508195 | Eluxadoline | 100mg | $640 | 2021-12-16 | Buy |
Properties
Melting point :>180°C (dec.)
Boiling point :834.2±65.0 °C(Predicted)
Density :1.284±0.06 g/cm3(Predicted)
storage temp. :Refrigerator
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
pka :4.01±0.10(Predicted)
color :White to Off-White
CAS DataBase Reference :864821-90-9
Boiling point :834.2±65.0 °C(Predicted)
Density :1.284±0.06 g/cm3(Predicted)
storage temp. :Refrigerator
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
pka :4.01±0.10(Predicted)
color :White to Off-White
CAS DataBase Reference :864821-90-9
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
Description
Eluxadoline, originally developed by Janssen and currently marketed by Allergan (formerly Actavis), was approved in May 2015 by the FDA for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Eluxadoline, an orally dosed agent, employs a unique mechanism for IBS-D treatment, as it functions simultaneously as a μ- and κ-opioid receptor agonist and a δ- opioid receptor antagonist, leading to a first-in-class therapy for treatment of IBS-D. Specifically, in animal studies, eluxadoline was found to interact with opioid receptors in the gut, inhibiting neurogenically mediated secretion and reducing intestinal contractility. Additionally, the treatment led to a decrease in stress-induced acceleration of upper GI transit without causing rebound constipation, earning its mark as a first-line therapeutic treatment for IBS-D. In two phase III clinical trials of over 2400 patients with IBS-D, patients taking eluxadoline showed a greater improvement toward the end point (≥30% improvement from their baseline IBS-D score on at least 50% of days treated with eluxadoline) compared to patients treated with placebo.Related product price
- Axitinib
$39-1154 - Bicalutamide
$30-1593.9
Suppliers and manufacturers
Capot Chemical Co.,Ltd.
Beijing Cooperate Pharmaceutical Co.,Ltd
Henan Tianfu Chemical Co.,Ltd.
ATK CHEMICAL COMPANY LIMITED
Nanjing Dolon Biotechnology Co.,Ltd.
Hangzhou Cyanochem Co., Ltd.
Chongqing Chemdad Co., Ltd
Xi'an MC Biotech, Co., Ltd.
